Alpine Immune Sciences Valuation

Alpine Immune Investor Information

About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.64. Alpine Immune Sciences last dividend was issued on the 25th of July 2017. The entity had 1:4 split on the 25th of July 2017. Based on the measurements of operating efficiency obtained from Alpine Immune's historical financial statements, Alpine Immune Sciences is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.

Alpine Immune Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Alpine Immune has an asset utilization ratio of 15.42 percent. This suggests that the Company is making $0.15 for each dollar of assets. An increasing asset utilization means that Alpine Immune Sciences is more efficient with each dollar of assets it utilizes for everyday operations.

Alpine Immune Ownership Allocation

Alpine Immune holds a total of 68.6 Million outstanding shares. The majority of Alpine Immune Sciences outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alpine Immune Sciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alpine Immune. Please pay attention to any change in the institutional holdings of Alpine Immune Sciences as this could imply that something significant has changed or is about to change at the company. Also note that nearly two million seven hundred eighty-five thousand fifty-nine invesors are currently shorting Alpine Immune expressing very little confidence in its future performance.

Alpine Immune Profitability Analysis

The company reported the previous year's revenue of 58.88 M. Net Loss for the year was (32.18 M) with loss before overhead, payroll, taxes, and interest of (40.18 M).

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

If you are still planning to invest in Alpine Immune Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alpine Immune's history and understand the potential risks before investing.